Hypoaldosteronism

Hypoaldosteronism is an endocrine and nephrological condition characterized by reduced biological availability of aldosterone, caused either by insufficient production or by peripheral resistance to mineralocorticoid activity at the level of the distal nephron. Because aldosterone is the main effector of the renin-angiotensin-aldosterone system in the fine regulation of sodium reabsorption and potassium and hydrogen ion excretion, its functional deficiency typically produces a clinical spectrum dominated by hyperkalemia, a tendency toward hyperchloremic metabolic acidosis and, in more severe forms or in patients with limited physiological reserve, hemodynamic instability and impaired organ perfusion.

In clinical practice, hypoaldosteronism is not a single entity but a phenotype that may develop in very different settings, including primary adrenal insufficiency with mineralocorticoid deficiency, kidney disorders associated with reduced renin production and consequently inappropriately low aldosterone, medications that suppress the renin-angiotensin cascade, and genetic syndromes in which the mineralocorticoid receptor or distal transport channels do not respond adequately. Understanding the underlying mechanism is essential because the therapeutic strategy differs substantially between true hormonal deficiency and tubular resistance, and because clinical severity depends on the degree of hyperkalemia and the kidney’s ability to compensate.

The epidemiology of hypoaldosteronism is variable and partly underestimated because many forms are recognized only when hyperkalemia becomes persistent or clinically significant. In adults, the most common cause of functional hypoaldosteronism is the combination of reduced renin production and aldosterone levels that are inappropriately low relative to the severity of hyperkalemia, a condition commonly included within the spectrum of type 4 renal tubular acidosis. This phenotype is particularly common in patients with long-standing diabetes mellitus, diabetic kidney disease or tubulointerstitial kidney disease, in whom damage to the juxtaglomerular apparatus and tubular dysfunction impair the renin response and limit potassium excretion.

Its frequency increases with age because vulnerability depends both on the prevalence of chronic kidney disease and on the use of medications that interfere with regulation of the renin-angiotensin-aldosterone system (RAAS) and potassium excretion. In particular, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, mineralocorticoid receptor antagonists, potassium-sparing diuretics and certain medications that reduce aldosterone synthesis or availability can convert a fragile equilibrium into persistent hyperkalemia, especially when reduced glomerular filtration, dehydration, high potassium intake or insufficient distal sodium delivery are also present.

A separate epidemiological category includes hypoaldosteronism occurring as part of primary adrenal insufficiency. In these patients, mineralocorticoid deficiency is intrinsic to damage of the adrenal cortex and is associated with sodium loss and a risk of hypotension and adrenal crisis, with substantial clinical consequences, particularly during systemic stress. In neonates and children, genetically determined disorders, including some forms of pseudohypoaldosteronism and salt-wasting conditions caused by adrenal enzyme defects, may present dramatically with dehydration, hyponatremia and hyperkalemia.

The most important clinical risk factors include coexisting heart disease, combined use of medications that increase potassium, urinary tract obstruction or chronic uropathy, and conditions in which the kidney cannot increase potassium excretion because of reduced distal flow or abnormalities of tubular transport. In this setting, hypoaldosteronism often emerges as a complication of a broader systemic disorder, and its true epidemiology overlaps with that of chronic diseases affecting frail adults.

Aldosterone is secreted by the adrenal zona glomerulosa primarily in response to angiotensin II and hyperkalemia. In the distal nephron, the hormone acts through the mineralocorticoid receptor in principal cells of the collecting duct, increasing the activity of epithelial sodium channels and the sodium-potassium adenosine triphosphatase and creating an electronegative luminal environment that supports potassium secretion through specific channels. At the same time, the functional organization of the collecting duct also regulates hydrogen ion excretion. Aldosterone deficiency or resistance to its action therefore predisposes to impaired urinary acidification and normal anion gap metabolic acidosis.

From an etiological perspective, three major categories can be distinguished. The first is reduced aldosterone production caused by adrenal disease, as occurs in primary adrenal insufficiency, rarer forms of isolated hypoaldosteronism or enzymatic defects that impair mineralocorticoid synthesis. In these settings, aldosterone is genuinely low, and the phenotype often includes sodium loss, orthostatic hypotension and a tendency toward dehydration, with hyperkalemia that may become severe when kidney function is impaired or potassium intake is high.

The second category is reduced aldosterone production caused by low renin, which is typical of hyporeninemic hypoaldosteronism. In this condition, the main problem is not the ability of the zona glomerulosa to respond but the absence of an adequate upstream stimulus. Diabetes, tubulointerstitial kidney disease, renal vascular damage and certain conditions that reduce perfusion of the juxtaglomerular apparatus may cause low or inappropriately normal renin levels. The resulting aldosterone concentration is insufficient for the required degree of potassium excretion, particularly when reduced glomerular filtration and reduced distal sodium delivery coexist. These factors amplify potassium retention and promote type 4 hyperchloremic acidosis.

The third category is resistance to mineralocorticoid activity. In these conditions, aldosterone may be elevated, but the kidney does not translate the hormonal signal into an effective response involving sodium reabsorption and potassium secretion. Classic forms include type 1 pseudohypoaldosteronism, in which the defect involves the mineralocorticoid receptor or distal channels and causes salt wasting, hyperkalemia and dehydration, often early in life. Other syndromes have a more complex phenotype, with abnormalities of distal tubular transport causing hyperkalemia and acidosis in the presence of blood pressure that is often elevated. This makes it essential to distinguish aldosterone deficiency from primary abnormalities of tubular transport.

A substantial proportion of clinically relevant hypoaldosteronism is medication-induced. RAAS blockers reduce angiotensin II and therefore aldosterone production; mineralocorticoid receptor antagonists block its effector pathway; potassium-sparing diuretics directly reduce potassium secretion in the collecting duct; and certain medications may reduce aldosterone synthesis or alter system sensitivity. In patients with reduced kidney reserve, these interferences convert a physiological adaptation into a clinically relevant defect, producing persistent hyperkalemia that may limit cardioprotective and kidney-protective therapies unless it is managed through a structured approach.

The final pathophysiological pathway converges on a single mechanism: the inability to generate an adequate distal electrochemical gradient for potassium and proton excretion. This causes hyperkalemia, which may in turn further reduce ammonium production and the kidney’s ability to buffer acids, thereby worsening acidosis. The combination of hyperkalemia and acidosis is not merely a laboratory finding. It causes cardiac electrical instability, reduced muscle strength and increased clinical vulnerability, particularly in older patients and in those with heart disease or chronic kidney disease.

The clinical presentation of hypoaldosteronism is often less syndromic than that of other endocrine disorders because many manifestations arise from its biochemical consequences, particularly hyperkalemia and acidosis, and from the underlying disease responsible for the defect. In a substantial proportion of patients, onset is insidious and hyperkalemia is detected incidentally during monitoring for diabetes, hypertension or chronic kidney disease. The absence of specific symptoms does not imply a benign condition, because hyperkalemia can rapidly become dangerous in the presence of dehydration, infection, acute deterioration of kidney function or the introduction of interfering medications.

During medical history taking, symptoms, when present, may include fatigue, reduced exercise tolerance, cramps and a sensation of muscle weakness, sometimes worsening after increased dietary potassium intake or treatment changes. Palpitations, an irregular heartbeat or presyncopal episodes may occur when hyperkalemia affects cardiac conduction. In patients with primary adrenal insufficiency, the history may also include salt craving, weight loss, nausea, orthostatic hypotension and marked vulnerability during physical stress, reflecting the combined effects of mineralocorticoid and glucocorticoid deficiency.

On physical examination, findings may be limited in isolated hyporeninemic forms and may be dominated by signs of the underlying disorder, such as diabetic neuropathy, evidence of kidney disease or hypertension. In salt-wasting forms, hypotension, compensatory tachycardia, signs of dehydration and reduced peripheral perfusion may be present. Clinical assessment must include careful evaluation of volume status and arrhythmic risk because the transition from apparently tolerated hyperkalemia to electrical instability may be precipitated by intercurrent events.

In neonates and children, the clinical presentation may be dominated by dehydration, poor growth, vomiting, lethargy and signs of hypovolemic shock, with severe hyperkalemia and acidosis. Prompt recognition is essential because physiological compensatory capacity is limited and the cardiac consequences of hyperkalemia may develop rapidly. In adults as well, hypoaldosteronism becomes clinically evident mainly when kidney reserve is limited and the ability to eliminate potassium is already impaired.

Hypoaldosteronism should be suspected in the presence of persistent hyperkalemia that cannot be adequately explained by advanced kidney failure, excessive potassium intake or clear acute causes. A key finding is normal anion gap metabolic acidosis, which is often hyperchloremic and suggests impaired distal secretion of hydrogen ions and ammonium consistent with a mineralocorticoid defect or type 4 renal tubular acidosis.

Suspicion should be particularly high in patients with diabetes, diabetic kidney disease or tubulointerstitial kidney disease, even when glomerular filtration is only moderately reduced, because hyporeninemic hypoaldosteronism may develop before end-stage kidney failure. Similarly, the association between hyperkalemia and treatment with ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists or potassium-sparing diuretics should be interpreted as possible unmasking of an already fragile equilibrium rather than as an isolated adverse effect.

When hypotension, salt craving, weight loss and systemic symptoms are present, hypoaldosteronism should be considered in the context of possible primary adrenal insufficiency, particularly when hyponatremia and hyperkalemia coexist. In neonates and infants, dehydration associated with hyponatremia and hyperkalemia requires rapid consideration of adrenal synthesis defects, genetic forms of mineralocorticoid resistance and other causes of salt wasting, because urgent management of hyperkalemia and volume depletion takes priority.

Attention must also be given to situations in which aldosterone is present but ineffective. When a patient has hyperkalemia and acidosis with aldosterone concentrations that are not low or are even elevated, the diagnostic reasoning should shift toward impaired tubular responsiveness or a primary defect of distal transport. In this setting, the combination of renin and aldosterone measurements is not an ancillary finding but the key to avoiding incorrect diagnoses and ineffective treatment.

The diagnosis of hypoaldosteronism requires a rational pathway beginning with confirmation of hyperkalemia and characterization of acid-base status, followed by demonstration of the mineralocorticoid defect and identification of its level of origin. The first step is to confirm that hyperkalemia is genuine and persistent by excluding preanalytical hemolysis and assessing creatinine, estimated glomerular filtration rate, bicarbonate, chloride and glucose. The combination of hyperkalemia and hyperchloremic acidosis suggests impaired distal excretion of potassium and protons. Medication review is mandatory because many medications may reduce aldosterone production or block its activity and may represent either the primary cause or the factor that reveals a pre-existing dysfunction.

The core of the assessment is measurement of aldosterone and renin, interpreted in relation to sodium intake, posture and kidney function. Low aldosterone with elevated renin suggests a primary adrenal defect in mineralocorticoid production or impaired synthesis. Low aldosterone with low or inappropriately normal renin suggests hyporeninemic hypoaldosteronism, which is typical of diabetes and tubulointerstitial kidney disease. Aldosterone that is not low in the presence of significant hyperkalemia makes tubular resistance or a defect in distal transport more likely, because the response to the hormonal signal is inadequate.

Diagnostic assessment of hypoaldosteronism

• Confirmation of the phenotype: persistent hyperkalemia with measurement of bicarbonate and chloride to identify hyperchloremic metabolic acidosis consistent with a distal defect.
• Review of iatrogenic causes: identification of medications that reduce aldosterone activity or potassium excretion and assessment of dehydration, infections or acute deterioration of kidney function as precipitating factors.
• Definition of the level of the defect: measurement of renin and aldosterone to distinguish adrenal deficiency, hyporeninemic hypoaldosteronism and mineralocorticoid resistance.
• Assessment of the etiological context: investigation for adrenal insufficiency, diabetic or tubulointerstitial kidney disease, urinary obstruction and genetic conditions in early-onset or familial cases.

When global adrenal deficiency is suspected, the assessment should be extended to glucocorticoid function using appropriate dynamic testing, with evaluation of autoantibodies and adrenal imaging according to the clinical indication. In patients with a hyporeninemic phenotype, it is important to define the stage of kidney disease and assess for autonomic neuropathy and tubulointerstitial abnormalities that may reduce the renin response. When mineralocorticoid resistance or a genetic syndrome is suspected, age at onset, family history, sodium and potassium trends and blood pressure profile guide further specialist assessment, sometimes including targeted genetic testing.

Urinary data may help assess the kidney’s ability to excrete potassium and the consistency of the overall phenotype, although reduced kidney function and diuretic therapy may alter their interpretation. In practice, an effective diagnosis is one that establishes a coherent relationship among the biochemical phenotype, the renin-aldosterone profile and the clinical context, because this triangulation allows selection of a treatment that is both causal and safe.

A clinically useful classification of hypoaldosteronism is based on the mechanism and anatomical level of the defect because these factors determine both the clinical presentation and the response to treatment. The first category includes forms caused by reduced aldosterone production, with renin typically elevated, and commonly associated with primary adrenal insufficiency or selective defects of mineralocorticoid synthesis. In these patients, the dominant problem is sodium loss with hypotension and hypovolemia, while hyperkalemia is an indicator of severity and risk, particularly when kidney function is impaired.

The second category includes hyporeninemic hypoaldosteronism, in which low or inappropriately normal renin leads to aldosterone concentrations that are insufficient for the potassium load. This form is typical of adults with diabetes and kidney disease and is often associated with type 4 renal tubular acidosis, producing hyperkalemia and hyperchloremic acidosis that may be intermittent or persistent. Severity is strongly influenced by glomerular filtration, distal sodium delivery, potassium intake and concomitant therapy.

The third category includes forms caused by mineralocorticoid resistance, in which the hormonal signal fails to produce an adequate tubular response. Some forms present early and severely with salt wasting, dehydration and marked hyperkalemia. In others, blood pressure and volume balance may differ, and the phenotype may include hyperkalemia and acidosis despite blood pressure that is not low, making specialist assessment essential. In these conditions, the response to fludrocortisone may be limited or absent, and treatment focuses on strategies that increase potassium excretion and correct acidosis.

The clinical severity of hypoaldosteronism can be stratified according to the potassium concentration, the presence of electrocardiographic abnormalities, the severity of acidosis, hemodynamic stability and residual kidney function. Mild forms may be managed through medication and dietary adjustments with monitoring. Moderate to severe forms require prompt intervention to prevent arrhythmias and clinical deterioration, particularly when heart disease, kidney failure, infection or other conditions capable of rapidly worsening hyperkalemia coexist.

Treatment of hypoaldosteronism is based on three objectives: reducing the immediate risk associated with hyperkalemia and acidosis, correcting the mineralocorticoid defect when possible, and treating the underlying cause. The strategy must be individualized because adrenal deficiency requires hormonal replacement, whereas hyporeninemic hypoaldosteronism often requires medication optimization and potassium management. In resistant forms, the main objective is to increase potassium elimination and correct acidosis, often without the possibility of effectively replacing the hormone.

When hyperkalemia is significant or accompanied by electrocardiographic abnormalities, the priority is cardiac stabilization and rapid reduction of potassium according to emergency protocols. After the acute phase has been controlled, long-term management aims to prevent recurrence by identifying and removing precipitating factors. Medication review is central and may include reducing or replacing potassium-sparing diuretics, reassessing ACE inhibitors and angiotensin receptor blockers according to the risk-benefit balance, and avoiding combinations that increase potassium, particularly in chronic kidney disease.

In true mineralocorticoid deficiency, treatment with fludrocortisone is the most direct intervention, with dose titration based on blood pressure, signs of volume expansion, sodium and potassium concentrations. In patients with primary adrenal insufficiency, mineralocorticoid replacement is combined with glucocorticoid therapy and education regarding stress management because hemodynamic stability depends on the entire adrenocortical hormonal profile. The goal is to achieve a balance that normalizes electrolytes and blood pressure without causing volume overload, hypertension or iatrogenic hypokalemia.

In hyporeninemic hypoaldosteronism and type 4 renal tubular acidosis, treatment often combines dietary and pharmacological measures. Reduction of potassium intake must be balanced against nutritional requirements, while increasing distal sodium delivery with selected diuretics may improve potassium excretion when volume status allows. Correction of acidosis with bicarbonate may reduce hyperkalemia by improving ammoniagenesis and distal secretion and may provide long-term systemic benefits. When hyperkalemia limits cardioprotective and kidney-protective therapies, potassium binders may help maintain a more stable balance, with close monitoring of volume status and sodium according to the strategy used.

In mineralocorticoid resistance, fludrocortisone may be ineffective or insufficiently effective. Treatment therefore focuses on volume management, optimization of sodium intake according to the clinical condition, enhancement of potassium excretion and correction of acidosis. In children, specialist management is required to prevent dehydration and support growth and development, with close follow-up because therapeutic requirements may change rapidly during infections or changes in dietary intake.

In all cases, treatment must account for cardiorenal frailty. Hypoaldosteronism often occurs in clinically complex patients, and successful management depends on reducing hyperkalemia without precipitating deterioration of kidney function or volume overload, thereby maintaining a stable clinical course over time.

Follow-up of hypoaldosteronism is determined by the risk of recurrent hyperkalemia, the stability of kidney function and the treatment used. Laboratory monitoring includes potassium, sodium, bicarbonate and creatinine, with more frequent testing after any change in medications that interfere with the RAAS or after initiation or titration of fludrocortisone, diuretics, bicarbonate or potassium binders. In patients with chronic kidney disease, even small changes in glomerular filtration or hydration can significantly affect potassium, making a structured monitoring plan essential.

In patients receiving fludrocortisone replacement, follow-up should include blood pressure, symptoms of orthostatic intolerance, signs of volume expansion and electrolyte trends. The objective is to maintain stability without overtreatment, which may cause edema, hypertension and iatrogenic hypokalemia. Monitoring is particularly important in older patients and those with heart disease, who have a lower tolerance for volume overload.

In hyporeninemic hypoaldosteronism, follow-up is often linked to the underlying disease, particularly diabetes and kidney disease, and to the need to preserve cardioprotective and kidney-protective therapies while balancing the risk of hyperkalemia. Monitoring should include education regarding diet, recognition of precipitating factors such as dehydration or infection, and a clear plan for prompt reassessment of potassium after clinical or therapeutic changes. When arrhythmias or heart disease are present, an electrocardiogram or targeted cardiological assessment may be indicated if hyperkalemia has been significant or symptomatic.

Finally, in genetic forms or early-onset presentations, follow-up should be multidisciplinary, with attention to growth, development, nutritional status and the risk of acute episodes during intercurrent illnesses. Prevention of critical episodes depends on close monitoring and on a care pathway in which the patient and family understand the rationale for treatment and the relevant warning signs.

The prognosis of hypoaldosteronism depends on the underlying mechanism and on how rapidly stable control of potassium and acidosis is achieved. Iatrogenic forms and those caused by reversible factors generally have a favorable prognosis when the cause is recognized and corrected, with normalization of the electrolyte profile. In contrast, in forms associated with chronic kidney disease and diabetes, hyporeninemic hypoaldosteronism often represents a marker of tubular vulnerability and reduced physiological reserve, with a risk of recurrence during acute deterioration of kidney function or treatment changes.

The most important complications are related to hyperkalemia, which may cause potentially fatal arrhythmias and cardiac arrest, particularly when potassium rises rapidly or when medications that slow cardiac conduction are also present. Chronic metabolic acidosis may contribute to muscle catabolism and abnormalities of bone metabolism and, in advanced kidney disease, may accelerate frailty and functional decline. In patients with primary adrenal insufficiency, the combination of mineralocorticoid and glucocorticoid deficiency increases the risk of hemodynamic instability and acute events during stress, making prognosis closely dependent on treatment adherence and prevention of adrenal crises.

From a therapeutic perspective, prognosis is also influenced by the risk of iatrogenic complications. Excessive fludrocortisone may cause volume overload and hypertension, whereas strategies aimed at maintaining RAAS inhibition in patients with cardiorenal disease may increase the risk of hyperkalemia unless accompanied by dedicated control measures. A well-structured follow-up plan makes it possible to preserve cardioprotective and kidney-protective benefits while reducing electrolyte-related risk, which is often the main obstacle to optimal therapy.

Overall, hypoaldosteronism is a clinically significant condition because it highlights the balance between endocrine regulation and kidney function. When assessment is correct and treatment is consistent with the underlying mechanism, hyperkalemia can usually be controlled and prognosis may be favorable. When the defect is underestimated, recurrent hyperkalemia and cardiorenal instability become the main determinants of adverse outcomes.